You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昭衍新藥(603127.SH):上半年淨利預盈5032.43萬元到7548.65萬元
格隆匯 07-14 18:12

格隆匯7月14日丨昭衍新藥(603127.SH)公佈2025年半年度業績預吿,預計2025年1-6月份實現營業收入約人民幣63,514.65萬元到人民幣70,200.40萬元,,同比下降約17.3%到25.2%。

預計2025年1-6月份實現歸屬於上市公司股東的淨利潤約人民幣5,032.43萬元到人民幣7,548.65萬元,與上年同期的數據相比,將實現扭虧為盈。預計2025年1-6月份實現歸屬於上市公司股東的扣除非經常性損益的淨利潤約人民幣1,883.19萬元到人民幣2,824.79萬元。

本報吿期內受同業競爭影響,公司營業收入有所下降,銷售訂單的利潤空間被壓縮,毛利率同比降低,實驗室服務業務淨利潤同比下降,發生虧損。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account